Can Hibsago Let People Stop Hepatitis B Treatment? FDA Eligibility and the 19% Result
Short answer: The US Food and Drug Administration approved Hibsago (bepirovirsen) on October 20, 2026, as an add-on to existing antiviral therapy for a selected group of adults with chronic hepatitis B. In two phase 3 trials, about 19% met a laboratory-defined “functional cure” outcome 24 weeks after all hepatitis B treatment was stopped. That does not mean most patients can stop their current medicine, or that treatment ends as soon as Hibsago begins.
Who qualifies under the US approval?
The indication is limited to certain adults without cirrhosis. They must have taken an HBV antiviral for at least six months, have suppressed HBV in the blood, and have a hepatitis B surface antigen (HBsAg) level of 3,000 IU/mL or lower on an FDA-authorized test. The announcement does not cover every person with chronic hepatitis B, people with cirrhosis, or untreated infection. It is a US regulatory decision, not a Korean approval or reimbursement change.
Does Hibsago immediately replace a daily antiviral?
No. In the studied sequence, Hibsago was injected under the skin for up to 24 weeks while patients continued their existing antiviral. They remained on that antiviral for at least another 24 weeks after the final injection. Only patients who then met specified clinical and laboratory criteria could be considered for stopping the existing medicine. Treatment withdrawal required monitoring; it was not an automatic switch.
What does the 19% result mean?
B-Well 1 and B-Well 2 were randomized, double-blind phase 3 trials. At week 72, the functional-cure outcome occurred in 20% of the bepirovirsen group in B-Well 1 (127 of 650) and 19% in B-Well 2 (106 of 570), compared with no participants in the placebo groups. The trial defined the outcome as HBsAg loss plus HBV DNA below the quantification limit for at least 24 weeks after nucleos(t)ide analogue therapy was discontinued.
FDA summarized the same program another way: 24% of Hibsago recipients met criteria to stop their existing antiviral, and 19% still had viral control with undetectable HBsAg 24 weeks after stopping all HBV treatment. “Functional cure” describes these blood-test outcomes; it does not establish that every trace of HBV has been removed. Durability beyond the reported period and effects on long-term cirrhosis or liver-cancer risk still require follow-up.
What safety limits matter?
The FDA requires boxed warnings for serious liver reactions and low platelet counts, which can raise the risk of dangerous bleeding. Other warnings cover worsening kidney function, serious inflammatory reactions such as vasculitis, and risks from incorrect injection. Common reactions included injection-site problems, fever, fatigue and headache. Regular blood testing and clinical follow-up are part of safe use. The eGFR calculator is an educational estimate based on creatinine; it is not a basis for stopping medication or making treatment decisions.
What actually changes for patients?
Eligible US patients now have a finite add-on treatment that may create an opportunity to stop long-term antiviral therapy—but the reported success rate was roughly one in five, not everyone. This approval is unrelated to hepatitis B vaccination or interpreting vaccine-antibody results. Decisions about testing, eligibility and whether treatment can be withdrawn belong with a clinician managing the person’s liver disease.
Scope and review: FDA approval announcement dated October 20, 2026; phase 3 paper published May 28, 2026. Jurisdiction: United States. Population: selected noncirrhotic adults with chronic HBV meeting FDA criteria. Prepared by Life Choice Note as an independent personal-health explainer, not medical advice. Reviewed October 21, 2026.
Primary sources: US FDA approval announcement (October 20, 2026); Hou J et al., New England Journal of Medicine, Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection.